Pregabalin Capsule
Product Images NDC 70518-4024

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-4024). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for Pregabalin 25 mg capsules, dispensed in a quantity of 90 capsules. The label indicates it is a Schedule V controlled substance. The product is repackaged by Remedy Repack Inc. and manufactured by Novadoz Pharmaceuticals LLC, Pascataway, NJ. Directions advise seeing the package insert for use and storage at 20-25°C with permitted excursions.*

FDA Label Image

Equation (Pregabain Gault Equation)

A formula showing creatinine clearance (CLCr) calculation based on age, weight, and serum creatinine, including a multiplication factor for female patients. This text appears as part of clinical or pharmacokinetic information likely related to drug dosing or metabolism.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

This line graph depicts the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin at 25 mg, 100 mg, and 200 mg doses taken three times a day against placebo. The y-axis shows the percent of patients improved from 0% to 100%, and the x-axis shows pain improvement from >0% to 100%. Different dose groups are represented by distinct line styles with higher doses generally showing better improvement.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A Kaplan-Meier plot shows percent of patients improved versus percent improvement in pain from baseline comparing Pregabalin 100 mg three times a day (dashed line) to placebo (dotted line). The y-axis represents the percent of patients improved from 0 to 100%, and the x-axis shows increasing thresholds of percent improvement in pain from baseline, segmented by vertical lines.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken two times a day, compared to placebo. The graph displays four lines representing each treatment group, illustrating the relationship between dosage and patient improvement.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A chart depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 200 mg three times a day, 100 mg three times a day, and placebo. The chart shows descending lines representing patient improvement percentages for each treatment group across various pain improvement thresholds.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo groups. The vertical axis measures percent of patients improved (0 to 100), and the horizontal axis measures percent improvement in pain from baseline (0 to 100). The graph compares the efficacy over these parameters among the three groups.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

A bar chart showing responder rates (%) from two studies, E1 and E3. Study E1 presents data for placebo and doses of 50 mg, 150 mg, 300 mg, and 600 mg per day given BID, while Study E3 compares placebo with 600 mg per day doses given BID and TID. Each bar indicates the percentage of responders and sample size (N) below each dose group.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

A line graph depicting seizure reduction as median percent change from baseline versus dose in mg/day. Four groups are represented with different symbols: Stukly E1BID (filled circles), Stukly E2BID (open squares), Stukly E3BID (filled triangles), and Stukly E3TID (open triangles). The graph shows dose levels of 0, 50, 150, 300, and 600 mg/day with corresponding seizure reduction and p-values indicating statistical significance for the data points.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

A line graph illustrating the relationship between percent improvement in pain from baseline (x-axis) and percent of patients improved (y-axis). It compares four groups: Pregabalin 600 mg, 450 mg, 300 mg daily doses, and placebo, each represented by distinct line patterns.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve chart showing the estimated percentage of subjects without LTR (loss to remission or relapse) over time in days, comparing Pregabalin and placebo groups. The chart displays two stepwise survival curves with percentage on the y-axis (0% to 100%) and days on the x-axis (0 to 180 days).*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph comparing the percent of subjects improved over percent improvement from baseline to week 12 using BOCF for Pregabalin versus Placebo. The solid line represents Pregabalin showing higher improvement percentages than the dashed Placebo line across the measured range.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A line graph comparing the percent of subjects improved from baseline to week 16 using the BOCF method. The x-axis represents the percent improvement, and the y-axis represents the percent of subjects improved. The graph shows two lines: one solid line for Pregabalin and one dashed line for Placebo, with Pregabalin consistently having a higher percent of subjects improved across various improvement levels.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure of the active ingredient Pregabalin, displaying carbon, hydrogen, nitrogen, and oxygen atoms arranged to represent its molecular configuration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.